Retrospective analysis compares effectiveness and safety of benralizumab and dupilumab in adults with severe eosinophilic asthma, indicating equivalent safety profiles.
Key Points
This research aimed to compare the real-world effectiveness and safety of benralizumab and dupilumab in adults with severe eosinophilic asthma.
Conducted a retrospective analysis using TriNetX Research Network data from 110 healthcare organizations.
Included adults aged ≥18 with severe persistent asthma and eosinophilia, excluding those on mepolizumab or other biologics.
Performed 1:1 propensity-score matching across demographic and clinical covariates.
The incidence of acute respiratory failure was 5.7% for dupilumab and 7.0% for benralizumab (HR 0.77, p=0.19).
Major adverse cardiovascular events occurred in 6.6% of the dupilumab group and 6.9% of the benralizumab group (HR 0.91, p=0.73).
All-cause mortality was 2.0% for dupilumab compared to 2.6% for benralizumab (HR 0.75, p=0.39).